ArticleVirulence2017
S. oralis activates the Efg1 filamentation pathway in C. albicans to promote cross-kingdom interactions and mucosal biofilms.
Article in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- Cannabidiol (CBD) InhibitsInternational journal of dentistry · 2026Article
- The Impact of Bacterial-Fungal Interactions on Childhood Caries Pathogenesis.Pathogens (Basel, Switzerland) · 2025Article
- In vitro evaluation of tolerance ability of cross-kingdom biofilm towards oral dynamic fluctuations.BMC oral health · 2025Article
- Biofilms and oral health: nanotechnology for biofilm control.Discover nano · 2025Review
- Carbonizing technology enables Sanguisorbae Radix to inhibit yeast-to-hypha differentiation and biofilm formation in Candida albicans.PloS one · 2025Article
- The Oral Microbiome: A Key Determinant of Oral Health.Advances in experimental medicine and biology · 2025Review
- Biosynthesis and Characterization of Silver Nanoparticles and Simvastatin Association in Titanium Biofilms.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Molecular Determinants Involved in Candida albicans Biofilm Formation and Regulation.Molecular biotechnology · 2024Review
- Article
- A microfluidic organ-on-a-chip: into the next decade of bone tissue engineering applied in dentistry.Future science OA · 2023Review
- Surface adherence and vacuolar internalization of bacterial pathogens to the Candida spp. cells: Mechanism of persistence and propagation.Journal of advanced research · 2023Review
- Article
- Antimicrobial photodynamic therapy against oral biofilm: influencing factors, mechanisms, and combined actions with other strategies.Frontiers in microbiology · 2023Review
- Oral Microorganisms and Biofilms: New Insights to Defeat the Main Etiologic Factor of Oral Diseases.Microorganisms · 2022Article
- Cross-kingdom microbial interactions in dental implant-related infections: is Candida albicans a new villain?iScience · 2022Review
- In it together: Candida-bacterial oral biofilms and therapeutic strategies.Environmental microbiology reports · 2022Review
- Cross-kingdom interaction betweenFrontiers in microbiology · 2022Review
- Recent Advances and Opportunities in the Study ofFrontiers in cellular and infection microbiology · 2022Review
- Understanding Lactobacillus paracasei and Streptococcus oralis Biofilm Interactions through Agent-Based Modeling.mSphere · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Candida albicans and Streptococcus oralis are ubiquitous oral commensal organisms. Under host-permissive conditions these organisms can form hypervirulent mucosal biofilms. C. albicans biofilm formation is controlled by 6 master transcriptional regulators: Bcr1, Brg1, Efg1, Tec1, Ndt80, and Rob1. The objective of this work was to test whether any of these regulators play a role in cross-kingdom interactions between C. albicans and S. oralis in oral mucosal biofilms, and identify downstream target gene(s) that promote these interactions. Organotypic mucosal constructs and a mouse model of oropharyngeal infection were used to analyze mucosal biofilm growth and fungal gene expression. By screening 6 C. albicans transcription regulator reporter strains we discovered that EFG1 was strongly activated by interaction with S. oralis in late biofilm growth stages. EFG1 gene expression was increased in polymicrobial biofilms on abiotic surfaces, mucosal constructs and tongue tissues of mice infected with both organisms. EFG1 was required for robust Candida-streptococcal biofilm growth in organotypic constructs and mouse oral tissues. S. oralis stimulated C. albicans ALS1 gene expression in an EFG1-dependent manner, and Als1 was identified as a downstream effector of the Efg1 pathway which promoted C. albicans-S. oralis coaggregation interactions in mixed biofilms. We conclude that S. oralis induces an increase in EFG1 expression in C. albicans in late biofilm stages. This in turn increases expression of ALS1, which promotes coaggregation interactions and mucosal biofilm growth. Our work provides novel insights on C. albicans genes which play a role in cross-kingdom interactions with S. oralis in mucosal biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.